Helius Medical Technologies, Inc. provided financial guidance for the third quarter of 2023. The company expected to report third quarter revenues in range of $140,000 - $150,000, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023.
Helius Medical Technologies, Inc.
Equities
HSDT
US42328V8019
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.63 USD | -4.12% | -43.21% | -79.72% |
May. 07 | Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Tuesday as Traders Assess Earnings | MT |
May. 07 | Top Premarket Decliners | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-79.72% | 4.38M | |
+11.73% | 226B | |
+9.53% | 188B | |
+14.63% | 137B | |
+27.47% | 108B | |
-0.04% | 63.19B | |
+13.73% | 52.26B | |
+4.86% | 51B | |
+7.72% | 43.89B | |
+7.86% | 38.07B |
- Stock Market
- Equities
- HSDT Stock
- News Helius Medical Technologies, Inc.
- Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023